Breaking Finance News

ProQR Therapeutics NV (NASDAQ:PRQR) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Yesterday ProQR Therapeutics NV (NASDAQ:PRQR) traded 0.72% lower at $5.48. PRQR’s 50-day moving average is $5.45 and its two hundred day average is $5.05. The last stock price close is up 8.44% relative to the 200-day average, compared to the S&P 500 Index which has fallen -0.01% over the date range. Trading volume was was up over the average, with 20,089 shares of PRQR changing hands over the typical 17,814 shares..

Zacks Investment Research has upgraded ProQR Therapeutics NV(NASDAQ:PRQR) to Hold in a report released 9/17/2016.

Performance Graphic:

ProQR Therapeutics NV (NASDAQ:PRQR)

Also covering ProQR Therapeutics NV’s stock price target, a total of 3 equity analysts have issued a report on ProQR Therapeutics NV. The consensus target price is $22.67 with 0 rating the stock a strong buy, 0 rating the company a buy, 0 analysts rating the stock a hold, 0 rating the company to underperform, and finally 0 analysts rating the stock as sell.

ProQR Therapeutics NV has a one-year low of $3.48 and a 52 week high of $20.05. PRQR’s market capitalization is currently $0.0.

General Information About ProQR Therapeutics NV (NASDAQ:PRQR)

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, and is an oligonucleotide.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.